Similar articles

• Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial.

  Altundag O, Altundag K, Boruban C, Silay YS, Turen S. Altundag O, et al. Cancer. 2005 Nov 1;104(9):2033-4; author reply 2034. doi: 10.1002/cncr.21407. Cancer. 2005. PMID: 16161057 No abstract available.
• Phase II study of imatinib in patients with small cell lung cancer.

  Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T. Johnson BE, et al. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5880-7. Clin Cancer Res. 2003. PMID: 14676110 Clinical Trial.
• Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment.

  Gambacorti-Passerini C, Piazza R, Tornaghi L, Pilotti S, Pogliani E. Gambacorti-Passerini C, et al. J Natl Cancer Inst. 2004 Nov 17;96(22):1723-4. doi: 10.1093/jnci/djh330. J Natl Cancer Inst. 2004. PMID: 15547187 No abstract available.
• C-kit as a target in the treatment of acute myelogenous leukemia.

  Advani AS. Advani AS. Curr Hematol Rep. 2005 Jan;4(1):51-8. Curr Hematol Rep. 2005. PMID: 15610660 Review.
• Targeted molecules in small cell lung cancer.

  Murray N, Salgia R, Fossella FV. Murray N, et al. Semin Oncol. 2004 Feb;31(1 Suppl 1):106-11. doi: 10.1053/j.seminoncol.2003.12.021. Semin Oncol. 2004. PMID: 14981588 Review.